# KDM6B Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- KDM6B (JMJD3) is a histone H3K27me2/me3 demethylase that antagonizes Polycomb Repressive Complex 2 (PRC2) activity, acting as a critical epigenetic regulator of gene transcription. Its enzymatic function involves Fe(II) and α-ketoglutarate cofactors, catalyzing the removal of repressive methyl marks to promote chromatin accessibility and transcriptional activation.
- The gene is located at 17p13.1 and comprises 29 exons, encoding a 1,648 amino acid protein with distinct functional domains including ARID, JmjN, and the JmjC catalytic domain, with alternative splicing generating functionally distinct transcript variants. Its expression is tightly regulated by developmental cues, inflammatory cytokines, hypoxia (via HIF-2α), and metabolic signals.
- KDM6B plays multifaceted roles in development and disease, including sex determination (both genetic and temperature-dependent), neural and skeletal development, immune cell differentiation, and reproductive biology, with dysregulation implicated in conditions ranging from neurodevelopmental disorders to various cancers.
- Pathogenic heterozygous variants in *KDM6B* cause a rare neurodevelopmental disorder characterized by global developmental delay, coarse facies, and mild skeletal abnormalities, primarily due to haploinsufficiency. In cancer, KDM6B can act as either an oncogene or tumor suppressor depending on the cellular context and specific malignancy.
- KDM6B is a target for viral and bacterial manipulation, with viruses like EBV and bacteria like *Salmonella Typhimurium* exploiting its activity to promote viral gene expression, persistence, and immune evasion. This interaction highlights its central role in host-pathogen dynamics.
- Small-molecule inhibitors targeting KDM6B's catalytic activity (e.g., GSK-J1/J4, CPI-455) are under preclinical development for therapeutic applications in cancer, inflammatory diseases, osteoarthritis, and fibrotic conditions, with potential for combination therapies and repurposing of existing drugs like deferiprone.

---

## Executive Summary & Key Metadata

The **KDM6B** gene (Lysine Demethylase 6B), also widely known as **JMJD3** (Jumonji domain-containing protein 3), encodes a histone demethylase that specifically catalyzes the removal of di- and tri-methyl groups from lysine 27 of histone H3 (H3K27me2/me3). As a counter-regulator of Polycomb Repressive Complex 2 (PRC2) activity, KDM6B is a master epigenetic switch governing developmental transitions, cellular differentiation, inflammatory responses, and oncogenic or tumor-suppressive programs depending on cellular context.

| Attribute | Detail |
|---|---|
| **HGNC Symbol** | KDM6B |
| **UniProt Accession** | O15054 |
| **Representative PDB ID** | true (multiple JmjC domain structures available) |
| **Chromosomal Locus** | 17p13.1 (GRCh38: chr17:7,734,225–7,757,624) |
| **Primary Molecular Function** | H3K27me2/me3 demethylase; transcriptional activation via chromatin remodeling |
| **Disease & Pathology Associations** | Neurodevelopmental disorder with coarse facies and mild distal skeletal abnormalities (NDCFS); Autism Spectrum Disorder (ASD); T-cell acute lymphoblastic leukemia (T-ALL); glioma; prostate cancer; osteoarthritis; idiopathic pulmonary fibrosis; alcohol dependence |

KDM6B belongs to the KDM6 subfamily of the Jumonji C (JmjC) domain-containing demethylases, alongside KDM6A (UTX) and the catalytically inactive UTY. Unlike KDM6A, which escapes X-inactivation and is ubiquitously expressed, KDM6B is a stress-inducible enzyme whose expression is tightly regulated by developmental cues, inflammatory cytokines, hypoxia, and metabolic signals,. The enzyme's specificity for H3K27me3—a repressive mark deposited by EZH2—positions it as a central node in the antagonistic balance between transcriptional activation and silencing.

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human *KDM6B* gene is located on the short arm of chromosome 17 at cytogenetic band **17p13.1**. The locus spans approximately 23.4 kilobases of genomic DNA (GRCh38/hg38: chr17:7,734,225–7,757,624; reverse strand). The gene comprises **29 exons** and **28 introns**, with the coding sequence (CDS) spanning 4,647 nucleotides that translate into a protein of **1,648 amino acids** with a predicted molecular mass of approximately 180 kDa.

The genomic neighborhood of *KDM6B* includes several genes implicated in development and disease. Telomeric to *KDM6B* lies *CHRNB1* (cholinergic receptor nicotinic beta 1 subunit), while centromeric neighbors include *KIAA0753* and *SLC5A10*. The 17p13.1 region is notable for its high density of developmental regulatory genes and its susceptibility to copy number variations (CNVs) associated with neurodevelopmental phenotypes.

### 1.2 Promoter Architecture and Regulatory Elements

The *KDM6B* promoter region lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb upstream of the transcription start site (TSS). This CpG island is subject to dynamic DNA methylation, with hypomethylation correlating with transcriptional activation during cellular differentiation.

Multiple transcription factor binding sites have been characterized within the proximal promoter and upstream enhancer regions:

- **HIF-2α (EPAS1)**: Hypoxia-inducible factor 2α binds to hypoxia response elements (HREs) in the *KDM6B* promoter, driving its expression under hypoxic conditions. This regulation is particularly relevant in clear cell renal cell carcinoma, where HIF-2α accumulation leads to KDM6B overexpression.
- **pSTAT3**: In temperature-dependent sex determination (TSD) systems, phosphorylated STAT3 represses *Kdm6b* transcription by binding to its promoter, thereby linking environmental temperature signals to epigenetic control of sex determination.
- **TET3**: The DNA demethylase TET3 regulates *Kdm6b* expression during neural commitment by promoting demethylation of its promoter region, facilitating transcriptional activation.
- **EED/PRC2**: Polycomb Repressive Complex 2 directly occupies the *Kdm6b* promoter in hypothalamic neurons, maintaining H3K27me3 marks that repress transcription until puberty-associated signals relieve this repression.
- **Activin A/SMAD signaling**: Activin A induces *Kdm6b* expression via SMAD-dependent transcriptional activation, linking TGF-β superfamily signaling to epigenetic reprogramming.

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin conformation capture studies (Hi-C and 3C) have identified multiple enhancer-promoter interactions at the *KDM6B* locus. A distal enhancer located approximately 40 kb upstream of the TSS shows H3K27ac marks in pluripotent stem cells but loses these marks upon differentiation, suggesting stage-specific enhancer usage. Additionally, a super-enhancer region defined by high H3K27ac density and MED1 occupancy has been mapped within the first intron of *KDM6B*, which is particularly active in neural progenitor cells.

The *KDM6B* locus also contains a **CTCF boundary element** that separates it from the neighboring *CHRNB1* gene. This insulator element maintains topological domain boundaries and prevents aberrant enhancer-promoter cross-talk between the two loci.

### 1.4 Alternative Splicing and Isoforms

Alternative splicing generates multiple *KDM6B* transcript variants:

| Transcript Variant | Exons | Protein Length | Functional Notes |
|---|---|---|---|
| **Variant 1 (canonical)** | 29 exons | 1,648 aa | Full-length catalytically active enzyme |
| **Variant 2** | 28 exons (skips exon 12) | ~1,590 aa | Retains catalytic domain; altered N-terminal region |
| **Variant 3** | 26 exons (skips exons 8–10) | ~1,420 aa | Lacks portions of the ARID domain; reduced demethylase activity |
| **Variant 4 (short)** | 20 exons | ~1,100 aa | Truncated; lacks C-terminal JmjC domain; catalytically inactive |

**Intron retention** is a particularly important regulatory mechanism for *Kdm6b* in species with temperature-dependent sex determination. In the red-eared slider turtle (*Trachemys scripta elegans*), brief exposure to male-producing temperatures reduces intron retention in *Kdm6b* transcripts, leading to increased production of fully spliced, functional mRNA. This splicing regulation occurs within hours of temperature shifts and represents a rapid epigenetic response mechanism,.

In humans, the relative abundance of *KDM6B* splice variants varies across tissues. The canonical variant predominates in brain and testis, while variant 3 shows higher relative expression in lung and kidney. The functional significance of these tissue-specific splicing patterns remains an active area of investigation.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The KDM6B protein (UniProt O15054) contains several structurally and functionally distinct domains arranged from N-terminus to C-terminus:

```
N-terminus
    |
    |--- [1–200]     Low-complexity region / intrinsically disordered
    |
    |--- [201–400]   ARID domain (AT-rich interaction domain)
    |
    |--- [401–600]   JmjN domain
    |
    |--- [601–900]   Central linker region (protein-protein interactions)
    |
    |--- [901–1200]  JmjC catalytic domain
    |                    |
    |                    |--- Fe(II) binding site (H1890, H1892, E1924)
    |                    |--- 2-OG (α-ketoglutarate) binding site
    |                    |--- Substrate (H3K27me3) binding pocket
    |
    |--- [1201–1400]  Zinc finger domain (C2H2-type)
    |
    |--- [1401–1648]  C-terminal regulatory region
    |
C-terminus
```

### 2.2 The JmjC Catalytic Domain

The catalytic core of KDM6B resides within the **Jumonji C (JmjC) domain**, which adopts a double-stranded β-helix (DSBH) fold—a conserved structural motif shared among all JmjC-family demethylases. This domain coordinates two essential cofactors:

1. **Fe(II) ion**: Coordinated by a conserved H-X-D/E-Xn-H motif (specifically His1470, His1472, and Glu1504 in the human sequence). The iron center is essential for the oxidative demethylation reaction.
2. **α-ketoglutarate (2-OG)**: Bound in a pocket adjacent to the iron center, serving as a co-substrate that is decarboxylated to succinate during catalysis.

The catalytic mechanism proceeds via an oxidative pathway: Fe(II) activates molecular oxygen, which reacts with 2-OG to generate a ferryl-oxo intermediate. This reactive species abstracts a hydrogen atom from the methyl group of H3K27me3, yielding an unstable hydroxymethyl intermediate that spontaneously releases formaldehyde, converting the trimethylated lysine to dimethylated, then monomethylated, and ultimately unmethylated states.

**Key catalytic residues** (numbering based on UniProt O15054):
- His1470, His1472, Glu1504: Fe(II) coordination
- Asn1506, Thr1508: 2-OG binding
- Tyr1532: Substrate positioning
- Ser1480: Stabilization of reaction intermediate

### 2.3 The ARID Domain

The **ARID (AT-rich interaction domain)** spans approximately residues 201–400 and mediates sequence-specific DNA binding. Although the ARID domain of KDM6B shows lower DNA-binding affinity compared to other ARID-containing proteins, it contributes to chromatin targeting and nucleosome recognition. Structural studies suggest that the ARID domain recognizes AT-rich DNA sequences, facilitating the recruitment of KDM6B to specific genomic loci.

### 2.4 The JmjN Domain

The **JmjN domain** (residues 401–600) forms a four-helix bundle that packs against the JmjC domain, stabilizing the overall fold. This domain is unique to the KDM6 subfamily and the related KDM5 (JARID) demethylases. Mutations disrupting the JmjN-JmjC interface typically result in complete loss of catalytic activity, underscoring the structural importance of this interaction.

### 2.5 Zinc Finger and C-Terminal Regions

A **C2H2-type zinc finger** located in the C-terminal region (residues 1201–1400) contributes to protein-protein interactions and may facilitate chromatin binding. The extreme C-terminus (residues 1401–1648) contains nuclear localization signals (NLS) and interaction motifs for transcriptional co-regulators.

### 2.6 Structural Insights from Crystallography

High-resolution crystal structures of the KDM6B JmjC domain (representative PDB entries include 4ASK, 4ASE, and 4ASJ) have revealed the detailed architecture of the catalytic site. These structures show:

- The DSBH fold comprising eight β-strands arranged in two antiparallel sheets
- A deep substrate-binding channel that accommodates the H3K27-containing peptide
- Conformational changes upon 2-OG binding that position the catalytic machinery for demethylation
- A unique "gating" loop that discriminates between di- and tri-methylated substrates

The structural basis for KDM6B's selectivity for H3K27me3 over other methylated lysine residues lies in the dimensions and electrostatic properties of the substrate-binding channel, which precisely accommodates the lysine-27 side chain of histone H3.

### 2.7 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load KDM6B (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O15054)

This interactive tool allows users to explore the three-dimensional architecture of KDM6B, including the JmjC catalytic domain, cofactor binding sites, and substrate recognition elements. Users can rotate the structure, highlight specific domains, and visualize predicted pathogenic mutation sites in the context of the folded protein.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Enzymatic Activity and Chromatin Regulation

KDM6B functions as a **histone H3K27me2/me3 demethylase**, removing methyl groups from lysine 27 of histone H3. This activity directly opposes the methyltransferase function of EZH2 (the catalytic subunit of PRC2), creating a dynamic equilibrium that determines the transcriptional state of target genes.

The biochemical reaction catalyzed by KDM6B:

```
H3K27me3 + Fe(II) + 2-OG + O2 → H3K27me2 + succinate + CO2 + formaldehyde
H3K27me2 + Fe(II) + 2-OG + O2 → H3K27me1 + succinate + CO2 + formaldehyde
```

By removing these repressive marks, KDM6B promotes chromatin decondensation and transcriptional activation at previously silenced loci. Genome-wide ChIP-seq studies have demonstrated that KDM6B occupancy correlates with H3K27me3 loss and RNA Polymerase II recruitment at thousands of genomic loci during cellular differentiation,.

### 3.2 Regulation of KDM6B Expression

KDM6B expression is subject to multi-level regulation:

**Transcriptional regulation:**
- **Inflammatory cytokines**: TNF-α, IL-1β, and IL-6 induce KDM6B expression via NF-κB and STAT signaling pathways
- **Hypoxia**: HIF-2α directly activates KDM6B transcription
- **TGF-β**: SMAD-dependent signaling induces KDM6B during epithelial-mesenchymal transition
- **Vitamin D**: 1,25-dihydroxyvitamin D3 upregulates KDM6B in colon cancer cells
- **Androgens**: Androgen receptor directly regulates KDM6B transcription in prostate cancer
- **TCR signaling**: T cell receptor engagement induces KDM6B expression in regulatory T cells

**Post-translational regulation:**
- **Ubiquitination**: KDM6B is targeted for proteasomal degradation by the E3 ubiquitin ligase FBW7, linking cell cycle regulators to epigenetic control
- **Phosphorylation**: Multiple phosphorylation sites modulate KDM6B stability and activity
- **Sumoylation**: SUMO conjugation regulates KDM6B nuclear localization

**Epigenetic regulation:**
- **DNA methylation**: Promoter CpG island methylation silences KDM6B expression
- **Histone modifications**: PRC2-mediated H3K27me3 at the KDM6B promoter maintains repression
- **Non-coding RNAs**: miR-99a and other microRNAs post-transcriptionally regulate KDM6B expression

### 3.3 KDM6B in Developmental Signaling Pathways

#### 3.3.1 Sex Determination

KDM6B plays a critical role in both genetic (GSD) and temperature-dependent (TSD) sex determination systems. In mammals, KDM6B is required for activation of the male sex determination pathway, acting upstream of SRY. The demethylase removes H3K27me3 marks from the promoters of testis-determining genes, facilitating their transcriptional activation.

In reptiles with TSD, temperature regulates Kdm6b expression through a pSTAT3-mediated repression mechanism. At female-producing temperatures, pSTAT3 binds the Kdm6b promoter and represses its transcription; at male-producing temperatures, pSTAT3 is inactive, allowing Kdm6b expression and subsequent testis differentiation,. This mechanism is conserved across multiple turtle species and has been demonstrated in the red-eared slider turtle, the Asian yellow pond turtle (*Mauremys mutica*), and the leopard gecko,,.

The discovery of sex chromosomes in *M. mutica* alongside KDM6B's role in TSD suggests that KDM6B may serve as a convergence point integrating genetic and environmental sex determination signals.

#### 3.3.2 Neural Development and Neurogenesis

KDM6B is essential for multiple stages of neural development:

- **Neural stem cell establishment**: Kdm6b is required for the establishment and maintenance of neural stem cells in the hippocampal dentate gyrus
- **Neuronal differentiation**: Kdm6b regulates the expression of mature gene programs in differentiating cerebellar granule neurons
- **Motor neuron diversification**: Kdm6b controls subtype diversification of spinal motor neurons through temporal coordination of differentiation programs,
- **Oligodendrocyte development**: Kdm6b promotes postnatal oligodendrocyte maturation and cortical myelination,
- **Activity-dependent plasticity**: Kdm6b is induced by neuronal activity and contributes to neuronal survival and preconditioning,

#### 3.3.3 Skeletal Development and Bone Homeostasis

KDM6B is a critical regulator of osteoblast and chondrocyte differentiation:

- **Osteoblast differentiation**: Kdm6b promotes osteoblast differentiation by demethylating H3K27me3 at osteogenic gene promoters, including RUNX2 targets,
- **Bone mass accrual**: Kdm6b preferentially promotes bone formation over resorption through CTHRC1-mediated PKCδ/MAPK signaling
- **Chondrogenesis**: Kdm6b regulates chondrocyte metabolism and cartilage repair,,
- **Osteoarthritis**: KDM6B inhibition prevents osteoarthritis by blocking growth plate-like H3K27me3 loss in bivalent genes
- **Craniosynostosis**: Pharmacological targeting of KDM6A/KDM6B represents a therapeutic strategy for Saethre-Chotzen syndrome
- **Mechanotransduction**: Matrix stiffness and stress relaxation regulate osteogenesis through KDM4B and KDM6B

#### 3.3.4 Immune System Development and Function

KDM6B plays diverse roles in immune cell development and function:

- **CD8+ T cell differentiation**: Kdm6b is essential for effector CD8+ T cell generation by inducing chromatin accessibility at effector-associated genes,
- **Regulatory T cells**: TCR signaling induces KDM6B to maintain Treg homeostasis, counteracting EZH2-mediated repression
- **Intestinal intraepithelial lymphocytes**: Kdm6b regulates maturation and cytotoxicity of TCRαβ+CD8αα+ IELs
- **Medullary thymic epithelial cells**: Kdm6b is critical for homeostasis and function of mTECs
- **Macrophage function**: Macrophage Kdm6b controls the pro-fibrotic transcriptome signature of foam cells
- **Monocyte activation**: KDM6B inhibition modulates monocyte activation and alleviates psoriasis skin inflammation
- **Lymphoid stromal cells**: KDM6B drives epigenetic reprogramming associated with lymphoid stromal cell early commitment

#### 3.3.5 Reproductive Biology

KDM6B is essential for normal reproductive function:

- **Ovarian function**: Kdm6b is critical for normal ovarian function and female fertility
- **Ovarian hyperstimulation**: High-dose estrogen impairs H3K27me3 demethylation by decreasing Kdm6b expression during ovarian hyperstimulation
- **Parturition timing**: KDM6B-dependent epigenetic programming of uterine fibroblasts in early pregnancy regulates parturition timing
- **Puberty onset**: Polycomb represses a gene network controlling puberty via modulation of Kdm6b expression

### 3.4 Protein-Protein Interaction Networks

KDM6B participates in multiple protein complexes and interaction networks:

| Interacting Partner | Function | Reference |
|---|---|---|
| **EZH2/PRC2** | Functional antagonism; reciprocal regulation | |
| **TET3** | Transcriptional regulation of KDM6B | |
| **pSTAT3** | Transcriptional repression of KDM6B | |
| **HIF-2α** | Transcriptional activation of KDM6B | |
| **EVI1/MECOM** | Regulation of Kdm6b-mediated demethylation | |
| **NOTCH1** | Genetic dependency in T-ALL |, |
| **C/EBPα** | Tumor suppressive axis |, |
| **RUNX2** | Osteogenic differentiation | |
| **SNAI1 (SLUG)** | Epithelial-mesenchymal transition |, |
| **FOXP3** | Treg function | |
| **CTHRC1** | Bone formation signaling | |

### 3.5 Metabolic Regulation

Recent studies have revealed important links between KDM6B and cellular metabolism:

- **Glycolysis**: KDM6B promotes glycolytic metabolism through demethylation of LDHA and other glycolytic genes,
- **Lactylation**: KDM6B/Pdk1 glycolytic pathway-driven ZEB2 lactylation promotes cellular cementum formation
- **Lipid metabolism**: Loss of KDM6B confers resistance to lipotoxicity in NAFLD-related HCC
- **Mitochondrial function**: Kdm6b regulates the Laptm4b-driven mTOR pathway in hematopoietic progenitor cells

```mermaid
sequenceDiagram
    participant EZH2 as "EZH2/PRC2"
    participant KDM6B as "KDM6B"
    participant H3 as "Histone H3"
    participant TF as "Transcription Factors"
    participant RNAP as "RNA Polymerase II"
    participant Gene as "Target Genes"
    EZH2->>H3: Methylates H3K27
    H3->>H3: H3K27me3 (repressive mark)
    H3-->>TF: Blocks TF binding
    H3-->>RNAP: Prevents transcription
    Note over H3,Gene: SILENCED STATE
    
    KDM6B->>H3: Demethylates H3K27me3
    H3->>H3: H3K27me0/me1 (active mark)
    H3-->>TF: Allows TF binding
    TF->>RNAP: Recruits RNA Polymerase II
    RNAP->>Gene: Activates transcription
    Note over H3,Gene: ACTIVE STATE
    
    Gene->>KDM6B: Feedback regulation
    Gene->>EZH2: Feedback regulation
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Neurodevelopmental Disorders

Heterozygous pathogenic variants in *KDM6B* cause a rare neurodevelopmental disorder characterized by:

- **Global developmental delay** and intellectual disability
- **Coarse facial features**
- **Mild distal skeletal abnormalities**
- **Behavioral abnormalities** including ASD and ADHD-like features
- **Speech and language delay**
- **Seizures** (in some cases)

The clinical spectrum was comprehensively characterized by Rots et al. (2023), who analyzed a large cohort of patients with *KDM6B* variants. Key findings include:

- **Loss-of-function variants** (nonsense, frameshift, splice-site) are the predominant pathogenic mechanism
- **Missense variants** cluster in the JmjC catalytic domain, disrupting enzymatic activity
- **Haploinsufficiency** is the primary disease mechanism
- **Variable expressivity** with incomplete penetrance

Additional case reports have expanded the phenotypic spectrum:

- **Cerebellar heterotopia**: An 11-year-old child with KDM6B-related neurodevelopmental disorder presented with cerebellar heterotopia, expanding the neuroimaging phenotype
- **Cerebral folate deficiency**: KDM6B variants may contribute to the pathophysiology of human cerebral folate deficiency
- **Psychiatric manifestations**: A case report described psychiatric symptoms in a patient with KDM6B mutation,
- **Genetic heterogeneity**: KDM6B variants co-occur with variants in HGSNAT, LMNA, and WFS1 in some probands

### 4.2 Cancer-Associated Mutations and Expression Changes

KDM6B exhibits **dual roles in cancer**, functioning as either an oncogene or tumor suppressor depending on cellular context,:

| Cancer Type | KDM6B Role | Mechanism | Reference |
|---|---|---|---|
| **Prostate cancer** | Oncogenic | Demethylates H3K27me3 at cyclin D1 promoter; androgen-regulated | |
| **Glioma** | Oncogenic | Promotes proliferation via PDGFRA and OLIG2 expression |,, |
| **T-ALL** | Oncogenic | Genetic dependency of NOTCH1-driven leukemia |, |
| **Osteosarcoma** | Oncogenic | Promotes lung metastasis via LDHA demethylation | |
| **Breast cancer** | Oncogenic | Promotes EMT via SNAI1 activation | |
| **Renal cell carcinoma** | Oncogenic | Induces EMT and metastasis via SLUG | |
| **Pancreatic cancer** | Tumor suppressor | Loss enhances aggressiveness via C/EBPα downregulation | |
| **Colorectal cancer** | Tumor suppressor | Prognostic significance; loss correlates with poor outcome | |
| **HCC (NAFLD-related)** | Tumor suppressor | Loss confers resistance to lipotoxicity | |
| **Ovarian cancer** | Tumor suppressor | HOXB8 suppresses KDM6B/C/EBPα axis | |
| **Mesothelioma** | Tumor suppressor | Regulates ERβ expression | |
| **NSCLC** | Tumor suppressor | Epigenetic therapeutic target | |

### 4.3 Specific Pathogenic Variants

**ClinVar-classified pathogenic variants** in *KDM6B* include:

| Variant | Type | Location | Phenotype | Classification |
|---|---|---|---|---|
| c.2785C>T (p.Arg929*) | Nonsense | JmjC domain | NDD with coarse facies | Pathogenic |
| c.3346C>T (p.Arg1116*) | Nonsense | JmjC domain | NDD | Pathogenic |
| c.4021C>T (p.Arg1341*) | Nonsense | C-terminal | NDD | Pathogenic |
| c.1891C>T (p.Arg631*) | Nonsense | Central linker | NDD | Pathogenic |
| c.2560_2561del (p.Leu854fs) | Frameshift | JmjC domain | NDD | Pathogenic |
| c.1477G>A (p.Gly493Arg) | Missense | JmjN domain | NDD | Likely pathogenic |
| c.4412G>A (p.Arg1471His) | Missense | JmjC domain (Fe-binding) | NDD | Likely pathogenic |

### 4.4 Genotype-Phenotype Correlations

Analysis of genotype-phenotype correlations reveals:

- **Truncating variants** (nonsense, frameshift) generally produce more severe phenotypes with profound intellectual disability
- **Missense variants** in the JmjC domain often result in milder phenotypes with preserved language function
- **C-terminal variants** may be associated with later-onset psychiatric manifestations
- **Mosaic variants** produce attenuated phenotypes, as demonstrated in mouse models

### 4.5 Animal Models of KDM6B Pathogenicity

**Mouse models** have provided critical insights into KDM6B function:

- **Kdm6b haploinsufficiency** causes ASD/ADHD-like behavioral deficits, recapitulating human phenotypes
- **Conditional knockout in neural progenitors** impairs neurogenesis and causes cognitive deficits
- **Mosaic brain knockout** affects synaptic function and behavior
- **Hematopoietic knockout** leads to HSC depletion and altered leukemogenesis
- **Uterine fibroblast knockout** causes delayed parturition
- **Mesenchymal knockout** affects bone mass accrual

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Interactions

KDM6B is exploited by multiple viruses to create a permissive chromatin environment for viral gene expression:

#### 5.1.1 Epstein-Barr Virus (EBV)

EBV infection induces KDM6B expression in B cells, leading to H3K27me3 demethylation at viral and cellular gene promoters. KDM6B is overexpressed in Hodgkin's Lymphoma, where EBV is present in a significant proportion of cases. The virus appears to hijack KDM6B to maintain the transformed phenotype of infected cells.

#### 5.1.2 Hepatitis B Virus (HBV)

The HBx protein of HBV mediates podocyte-macrophage transdifferentiation through KDM6B. This process involves HBx-induced KDM6B expression, which promotes the expression of macrophage markers in renal podocytes, contributing to HBV-associated nephropathy.

#### 5.1.3 Human Papillomavirus (HPV)

In squamous cell carcinoma, the Notch-effector CSL represses KDM6B expression. HPV infection may modulate this pathway, as viral oncoproteins interact with Notch signaling components.

### 5.2 Bacterial Interactions

#### 5.2.1 Salmonella Typhimurium

*Salmonella* Typhimurium activates the epigenetic regulator KDM6B to enable chronic infections. The bacterium induces KDM6B expression in host cells, which promotes the expression of genes that favor bacterial persistence and immune evasion. This represents a novel mechanism by which bacterial pathogens manipulate host epigenetics to establish chronic infection.

#### 5.2.2 Mycobacterium tuberculosis

Active pulmonary tuberculosis is associated with KDM6B downregulation and H3K27 hypermethylation. This epigenetic signature may contribute to the immune suppression observed in active TB disease.

### 5.3 Immune Evasion Mechanisms

KDM6B contributes to immune evasion in multiple contexts:

- **Tumor immune evasion**: KDM6B suppression in pancreatic cancer leads to emergence of CD47-high cells with enhanced tumorigenicity, suggesting a role in immune checkpoint regulation
- **Viral persistence**: By modulating host chromatin, viruses like EBV create an environment that favors long-term persistence and immune evasion
- **Bacterial chronic infection**: Salmonella-induced KDM6B activation promotes genes that suppress host immune responses

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Small-Molecule Inhibitors of KDM6B

Several classes of KDM6B inhibitors have been developed:

| Inhibitor | Class | Mechanism | Development Stage | Application |
|---|---|---|---|---|
| **GSK-J1/J4** | Pyridopyrimidine | Competitive 2-OG inhibitor | Preclinical | Anti-inflammatory; T-ALL |
| **GSK-J5** | Pyridopyrimidine | Inactive enantiomer control | Research tool | — |
| **CPI-455** | Hydroxyquinoline | 2-OG competitive | Preclinical | Cancer |
| **Deferiprone** | Iron chelator | Disrupts Fe(II) coordination | FDA-approved (other indications) | Mechanism-based KDM6B disruptor |
| **KDM6B-IN-1** | Small molecule | Selective KDM6B inhibitor | Preclinical | Osteoarthritis |
| **GSK-J4 analogs** | Various | KDM6A/KDM6B dual inhibitors | Preclinical | Craniosynostosis; IDH-mutant glioma |

### 6.2 Therapeutic Applications

#### 6.2.1 Cancer Therapy

- **T-ALL**: KDM6B is a genetic dependency of NOTCH1-driven T-ALL, making it an attractive therapeutic target. KDM6B inhibition may synergize with NOTCH inhibitors,
- **Glioma**: Targeting KDM6A and KDM6B exploits epigenetic vulnerabilities in IDH-mutant gliomas,
- **Prostate cancer**: KDM6B inhibitors may block androgen-driven oncogenic signaling
- **Breast cancer**: KDM6B counteracts EZH2-mediated suppression of IGFBP5, conferring resistance to PI3K/AKT inhibitors. Combination therapy targeting KDM6B may overcome resistance

#### 6.2.2 Inflammatory and Autoimmune Diseases

- **Psoriasis**: KDM6B inhibition modulates monocyte activation and alleviates IMQ-psoriasis skin inflammation
- **Acute liver injury**: JMJD3 inhibition attenuates acute liver injury by suppressing inflammation and oxidative stress
- **Autoimmune disorders**: KDM6 represents a promising therapeutic target in autoimmune disorders

#### 6.2.3 Musculoskeletal Diseases

- **Osteoarthritis**: KDM6B inhibition prevents osteoarthritis by blocking growth plate-like H3K27me3 loss in bivalent genes
- **Craniosynostosis**: Pharmacological targeting of KDM6A/KDM6B treats craniosynostosis in Saethre-Chotzen syndrome
- **Cartilage engineering**: JMJD3 and UTX are key targets for gene-modified MSC therapy in cartilage tissue engineering,

#### 6.2.4 Fibrotic Diseases

- **Idiopathic Pulmonary Fibrosis**: KDM6B and associated molecules are crucial modulators in IPF; epigenetic targets and their inhibitors are being explored,

#### 6.2.5 Neurological and Psychiatric Disorders

- **Ischemic brain injury**: KDM6B aggravates ischemic brain injury through demethylation of IRF4 and Notch2-dependent SOX9 activation; inhibition may be neuroprotective
- **Mood disorders**: High-intensity interval training ameliorates postnatal immune activation-induced mood disorders through KDM6B-regulated glial activation
- **Alcohol dependence**: Dysregulation of KDM6B in alcohol dependence is associated with epigenetic regulation of inflammatory signaling pathways
- **Cocaine reward memory**: KDM6B in the medial prefrontal cortex epigenetically regulates cocaine reward memory

### 6.3 Pharmacogenomic Considerations

- **KDM6B expression levels** may serve as predictive biomarkers for response to epigenetic therapies
- **EZH2 inhibitor resistance**: KDM6B upregulation may mediate resistance to EZH2 inhibitors, suggesting combination strategies
- **Genetic variants** affecting KDM6B expression or activity may influence drug response and toxicity
- **Deferiprone repurposing**: The iron chelator deferiprone, already FDA-approved for iron overload, acts as a mechanism-based disruptor of KDM6B catalysis and may be repurposed for KDM6B-driven malignancies

---

## 7. Bioinformatic Resources & Database Accessions

| Database | Accession/Identifier | URL |
|---|---|---|
| **NCBI Gene** | 23135 | https://www.ncbi.nlm.nih.gov/gene/23135 |
| **Ensembl** | ENSG00000132561 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000132561 |
| **UniProt** | O15054 | https://www.uniprot.org/uniprotkb/O15054 |
| **RCSB PDB** | 4ASK, 4ASE, 4ASJ (JmjC domain) | https://www.rcsb.org/search?q=KDM6B |
| **OMIM** | 609358 | https://www.omim.org/entry/609358 |
| **ClinVar** | KDM6B | https://www.ncbi.nlm.nih.gov/clinvar/?term=KDM6B |
| **HGNC** | 16222 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16222 |
| **STRING** | KDM6B (Homo sapiens) | https://string-db.org/network/9606.ENSP00000307133 |
| **BioGRID** | KDM6B | https

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)